A new study published in the Journal of American Medical Association showed that nirsevimab offers protection against a ...

Nirsevimab-resistant respiratory syncytial virus variants remain rare, but continued molecular surveillance is crucial. Read ...

The incident occurred months after health authorities discovered the GP’s clinic had incorrectly stored vaccines, potentially ...

RSV leads to approximately 1.4 million hospitalizations and over 13,000 in-hospital deaths worldwide among infants under six ...

In the new study, 64% of pregnant people were vaccinated before giving birth, and 70% of newly born eligible babies got a monoclonal antibody treatment called nirsevimab. Combined, 80% of babies ...

Vermont has the second lowest state fatality rate in the US (146.3 per 100K; Hawaii 112.7/100K). Mississippi (462.8/100K) and ...

But the baby may not be protected from RSV as well as he would have been had his mother received Abrysvo during pregnancy, or he had received nirsevimab, Richmond said. “I would be offering the ...

AstraZeneca and Sanofi are leading the charge here with nirsevimab, a long-acting antibody designed to provide passive protection to infants through their first RSV season with a single dose.